Loading
Life sciences · Journal article
Scientific Reports · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatic cancer remains a highly aggressive malignancy with limited effective treatment options, highlighting the need for alternative therapeutic strategies. This study aimed to identify compounds that modulate natural killer (NK) cell activity and to evaluate their effects on NK cell–associated responses against pancreatic cancer cells. Usinghigh-throughput screening (HTS), four candidate compounds were identified, among which rosiglitazone induced the most prominent increase in the expression of NK cell surface receptors, including NKp30 and NKp46, in NK-92MI cells. Cell viability and protein expression were assessed using a WST-8 assay and western blot analysis, respectively. Co-culture experiments were performed to evaluate NK cell–associated effects on pancreatic cancer cells. Rosiglitazone did not affect the viability of pancreatic cancer cells (Panc-1 and BxPC-3) and showed a tendency to increase NK-92MI cell viability. In co-culture conditions, rosiglitazone-treated NK-92MI cells were associated with reduced viability of pancreatic cancer cells, increased apoptosis, and altered expression of apoptosis-related proteins. These findings suggest that rosiglitazone modulates NK-92MI cell activity and may enhance NK cell–associated responses against pancreatic cancer cells in vitro. Further studies are required to validate these observations and to clarify the underlying mechanisms.